Biomet still gaining from trauma buy in Q4
This article was originally published in Clinica
Biomet once again benefited from its purchase of Johnson & Johnson’s DePuy trauma business during its fourth fiscal quarter. Overall, sales grew 6% to $783.9m, but many of its franchises shrank (see table below). These losses were offset by 62% growth in Biomet’s sports, extremities and trauma unit, to $159.2m.